Skip to content

Impact of OCT on Outcomes in AMI

Impact of Optical Coherence Tomography on Long-term Clincal Outcomes in Patients With Acute Myocardial Infarction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05266547
Enrollment
1600
Registered
2022-03-04
Start date
2016-01-01
Completion date
2024-01-01
Last updated
2022-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

Tomography, Optical Coherence, STEMI, NSTEMI, Major adverse cardiovascular event

Brief summary

This protocol describes a retrospective, single-center study intended to test the impact of optical coherence tomography(OCT) on long term clincical outcomes in patients with acute myocardial infarction(AMI). All the patients will be followed by intracoronary OCT at medium follow-up of 3 years.

Interventions

DEVICEOCT guided coronary intervention

patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group

Sponsors

Beijing Luhe Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age≥18 years old * Patients undergo cardiac catheterization and percutaneous coronary intervention(PCI) for AMI(STEMI or NSTEMI) ST-segment elevation myocardial infarction was defined according to the universal definition of myocardial infarction, symptoms onset≤ 24h.NSTEMI was defined as elevated troponin levels and the absence of ST elevation at the time of diagnosis, PCI was performed within 24hours after symtoms onset. * Sufficient quality of the OCT recording allowing for CoreLab analysis.

Exclusion criteria

* ostial of Left main disease * Cardiogenic shock or severe hemodynamic instability * Severe renal insufficiency (creatinine clearance ≤30 mL/min) * Bacteraemia or septicaemia * Severe coagulation disorders * Patients with life expectancy less than 1 year * Patients who refuse to sign the informed consent form

Design outcomes

Primary

MeasureTime frameDescription
major adverse cardiovascular event3 yearincluding cardiovascualr death, myocardial infarction, and target lesion revascularization, target vessel revascularization

Countries

China

Contacts

Primary ContactJincheng Guo, M.D.
guojcmd@126.com8610-13521968844

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026